Spectranetics Cross-Pilot Laser Support Catheter Receives FDA Clearance
December 18, 2008 - Spectranetics Corp. this week said the FDA cleared the Cross-Pilot Laser Support Catheter used in ablation of arterial blockages.
The launch of the product will commence during the first quarter of 2009 in the U.S., Europe and Canada.
The Cross-Pilot is a laser support catheter for the 0.9 Turbo Elite Laser Ablation Catheter. The Cross-Pilot was designed to provide additional support for reaching distal lesions. The braid reinforced catheter construction and hydrophilic coating allow for better pushability through distal vessels and the angled tip allows for quicker access to branched anatomy, the company said. The Cross-Pilot Laser Support Catheter is currently offered in 125 cm length and straight and angled tip configurations.
Spectranetics said it manufactures the only excimer laser approved in the U.S., Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The company’s disposable catheters use high-energy “cool” ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads.
For more information: www.spectranetics.com
More like this
- Spectranetics Files Pre-IDE FDA for Treatment of In-Stent Restenosis in the Legs
- Spectranetics Asks FDA to Treat In-Stent Restenosis in the Legs
- Laser Ablation System Assists Removal of 975 Cardiac Leads
- Laser Assessed to Treat In-Stent Restenosis
- Spectranetics Announces First Laser Lead Extraction Procedures in Japan